← Leaderboards
Samer Farah
F Square Medical Llc
$2,293,428
Attributed
$2,293,428
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2021–24$2M$1.5M$1M$500K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$2,293,428 · 2
By mechanism
R44$1,999,872 · 1
R43$293,556 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Diabetic Retinopathy”
- Barbara Halina Braffett · George Washington University$14,825,594
- Ionut Bebu · George Washington University$14,825,594
- Bradley David Gelfand · University Of Virginia$5,706,440
- Ashay D Bhatwadekar · Indiana University Indianapolis$4,941,043
- Elizabeth Ann Sugar · Johns Hopkins University$4,889,715
- Ji Yi · Johns Hopkins University$4,452,955
Research focus
Diabetic RetinopathyDiagnostic BiomarkerCorneaDevicesDiagnosisDesignAngle-Closure GlaucomaAdultAqueousDevice Or Instrument DevelopmentAge Related Macular DegenerationAcuteAmericanCorneal EndotheliumBiological MarkersBlindnessAnterior ChamberCataractChronicCiliary BodyAqueous HumorCommercializationCollaborationsDisability
Grant awards (3)
Development of the First-ever Safe and Effective Anterior Chamber Paracentesis Instrument to Treat and Diagnose Ocular Diseases$1,093,927
R44 · FY2024 · EY · contact PI
Development of the First-ever Safe and Effective Anterior Chamber Paracentesis Instrument to Treat and Diagnose Ocular Diseases$905,945
R44 · FY2023 · EY · contact PI
Development of the First-ever Safe and Effective Anterior Chamber Paracentesis Instrument to Treat and Diagnose Ocular Diseases$293,556
R43 · FY2021 · EY · contact PI